Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Last trade$1.33
Day change-$0.16 (-10.74%)
Day range$1.29 – $1.52
Volume429,499
Market cap$47M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$46.85M
Price / earnings
4.14×
Price / book
1.55×
Price / sales
1.34×
EV / sales
0.3×
EV / EBITDA
1.06×
Profitability
Earnings per share
$0.36
Return on assets
28.16%
Return on equity
37.32%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.08×
Quick ratio
4.08×
Cash ratio
3.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.25M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ATNM, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$35M
$0
$0
$90K
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$35M
$0
$0
$90K
$0
$0
$0
$0
Selling, general and administrative
$2.06M
$1.7M
$2.12M
$1.53M
$2.62M
$8.94M
$2.69M
$2.83M
Research and development
$5.38M
$4.2M
$4.3M
$4.25M
$4.88M
$7.7M
$4.81M
$9.77M
Total operating expenses
$7.44M
$5.9M
$6.41M
$5.78M
$7.5M
$16.64M
$7.51M
$12.6M
Operating income
$27.57M
-$5.9M
-$6.41M
-$5.69M
-$7.5M
-$16.64M
-$7.51M
-$12.6M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$27.9M
-$5.52M
-$5.94M
-$5.13M
-$6.88M
-$15.94M
-$6.65M
-$11.57M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$27.9M
-$5.52M
-$5.94M
-$5.13M
-$6.88M
-$15.94M
-$6.65M
-$11.57M
Net income attributable to common shareholders
$27.9M
-$5.52M
-$5.94M
-$5.13M
-$6.88M
-$15.94M
-$6.65M
-$11.57M
EBITDA
$28M
-$5.87M
-$6.86M
-$5.49M
-$7.14M
-$16.59M
-$7.92M
-$12.4M
Basic earnings per share
$0.89
-$0.18
-$0.19
-$0.16
-$0.22
-$0.51
-$0.21
-$0.37
Diluted earnings per share
$0.89
-$0.18
-$0.19
-$0.16
-$0.22
-$0.51
-$0.21
-$0.37
Recent news
Company coverage with links to the original publishers.
The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.
The targeted alpha therapy market is experiencing rapid growth driven by advancements in alpha emitters like Actinium-225, Astatine-211, and Lead-212 across clinical stages. Over 30 drugs are in clinical trials, with promising results in treating metastatic and drug-resistant cancers including prostate cancer and hepatocellular carcinoma. Major pharmaceutical companies and emerging biotech firms are actively developing these therapies, with recent M&A activity including AstraZeneca's acquisition of Fusion Pharmaceuticals and Bristol Myers Squibb's acquisition of RayzeBio, positioning targeted alpha therapy as a future pillar of precision medicine.
A new market research report reveals targeted alpha therapies (TAT) for cancer treatment are projected to grow from $199.6 million in 2024 to $1.1 billion by 2030, with a 44% CAGR, driven by precision medicine and unmet oncology treatment needs.
Rosen Law Firm is encouraging investors in Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to seek legal counsel before the May 27 deadline for a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the likelihood of its Iomab-B drug candidate being approved by the FDA.
Rosen Law Firm is encouraging investors of Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to secure legal counsel before the May 27, 2025 deadline for a securities class action lawsuit.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.